Top

Published in:

01-08-2019 | Original Paper

Is oxidized low-density lipoprotein the connection between atherosclerosis, cardiovascular risk and nephrolithiasis?

Authors: Augustus Cesar Pinto de Freitas, Leuridan Cavalcante Torres, Maria do Carmo Menezes Bezerra Duarte, Marina Cadena da Matta, Dulce Elena Casarini, Nestor Schor

Published in: Urolithiasis | Issue 4/2019

Abstract

Nephrolithiasis is considered a systemic disease. A link has been established between nephrolithiasis, cardiovascular disease (CVD), the metabolic syndrome and atherosclerosis. A significant correlation has been found between the high levels of oxidized low-density lipoprotein (oxLDL) and CVD and atherosclerosis, including coronary and femoral artery disease. To the best of our knowledge, oxLDL has not been evaluated in patients with nephrolithiasis. This study aimed to evaluate serum levels of oxLDL, anti-oxLDL antibodies (oxLDL-ab) and other markers of atherosclerosis in patients with nephrolithiasis, according to the severity of the disease. The population sample consisted of 94 patients of 30–70 years of age with no symptoms of CVD who presented with renal calculi documented by ultrasonography, abdominal X-ray or computed tomography. The patients were divided into two groups: Group 1 (≥ 3 stones) and Group 2 (1–2 stones). A comparison control group was formed with 21 healthy individuals. Enzyme-linked immunosorbent assays were used to assess oxLDL and oxLDL-ab. Lipid peroxidation indexes were also analyzed. Median serum oxLDL values were higher in Groups 1 and 2 compared to the control group (≥ 3 stones, p = 0.02; 1–2 stones, p = 0.03). Median serum anti-oxLDL antibody levels were lower in the patients in Group 1 compared to the controls (p = 0.03). There was no significant difference in the oxLDL/oxLDL-ab ratio between patients and controls. These findings suggest that this may be the link between nephrolithiasis and the greater incidence of atherosclerosis and cardiovascular disease in patients with kidney stones.

Khan SR (2012) Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res 40:95–112. https://doi.org/10.1007/s00240-011-0448-9 CrossRefPubMedCentralPubMed

Khan SR, Canales BK (2015) Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43(Suppl 1):109–123. https://doi.org/10.1007/s00240-014-0705-9 CrossRefPubMed

Shoag J, Tasian GE, Goldfarb DS, Eisner BH (2015) The new epidemiology of nephrolithiasis. Adv Chronic Kidney Dis 22:273–278. https://doi.org/10.1053/j.ackd.2015.04.004 CrossRefPubMed

Pfau A, Knauf F (2016) Update on nephrolithiasis: core curriculum 2016. Am J Kidney Dis 68:973–985. https://doi.org/10.1053/j.ajkd.2016.05.016 CrossRefPubMed

Wong YV, Cook P, Somani BK (2015) The association of metabolic syndrome and urolithiasis. Int J Endocrinol 2015:570674. https://doi.org/10.1155/2015/570674 CrossRefPubMedCentralPubMed

Worcester EM, Coe FL (2010) Clinical practice. Calcium kidney stones. N Engl J Med 363:954–963. https://doi.org/10.1056/NEJMcp1001011 CrossRefPubMedCentralPubMed

Sakhaee K, Maalouf NM, Sinnott B (2012) Clinical review. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 97:1847–1860. https://doi.org/10.1210/jc.2011-3492 CrossRefPubMedCentralPubMed

Gambaro G, Trinchieri A (2016) Recent advances in managing and understanding nephrolithiasis/nephrocalcinosis. F1000Res. https://doi.org/10.12688/f1000research.7126.1 PubMedCentralCrossRefPubMed

Johri N, Cooper B, Robertson W, Choong S, Rickards D, Unwin R (2010) An update and practical guide to renal stone management. Nephron Clin Pract 116:c159–c171. https://doi.org/10.1159/000317196 CrossRefPubMed

10.

Jeong IG, Kang T, Bang JK, Park J, Kim W, Hwang SS, Kim HK, Park HK (2011) Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney Dis 58:383–388. https://doi.org/10.1053/j.ajkd.2011.03.021 CrossRefPubMed

11.

Hamano S, Nakatsu H, Suzuki N, Tomioka S, Tanaka M, Murakami S (2005) Kidney stone disease and risk factors for coronary heart disease. Int J Urol 12:859–863. https://doi.org/10.1111/j.1442-2042.2005.01160.x CrossRefPubMed

12.

Gambaro G, Ferraro PM, Capasso G (2012) Calcium nephrolithiasis, metabolic syndrome and the cardiovascular risk. Nephrol Dial Transpl 27:3008–3010. https://doi.org/10.1093/ndt/gfs139 CrossRef

13.

Ramaswamy K, Shah O (2014) Metabolic syndrome and nephrolithiasis. Transl Androl Urol 3:285–295. https://doi.org/10.3978/j.issn.2223-4683.2014.06.03 PubMedCentralCrossRefPubMed

14.

Joshi S, Peck AB, Khan SR (2013) NADPH oxidase as a therapeutic target for oxalate induced injury in kidneys. Oxid Med Cell Longev 2013:462361. https://doi.org/10.1155/2013/462361 CrossRefPubMedCentralPubMed

15.

Khan SR (2014) Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol 3:256–276. https://doi.org/10.3978/j.issn.2223-4683.2014.06.04 PubMedCentralCrossRefPubMed

16.

Chung HJ (2014) The role of Randall plaques on kidney stone formation. Transl Androl Urol 3:251–254. https://doi.org/10.3978/j.issn.2223-4683 PubMedCentralCrossRefPubMed

17.

Coe FL, Evan AP, Worcester EM, Lingeman JE (2010) Three pathways for human kidney stone formation. Urol Res 38:147–160. https://doi.org/10.1007/s00240-010-0271-8 CrossRefPubMedCentralPubMed

18.

Bagga HS, Chi T, Miller J, Stoller ML (2013) New insights into the pathogenesis of renal calculi. Urol Clin N Am 40:1–12. https://doi.org/10.1016/j.ucl.2012.09.006 CrossRef

19.

Shavit L, Girfoglio D, Vijav V, Goldsmith D, Ferraro PM, Moochhala SH, Unwin R (2015) Vascular calcification and bone mineral density in recurrent kidney stone formers. Clin J Am Soc Nephrol 10:278–285. https://doi.org/10.2215/CJN.06030614 CrossRefPubMedCentralPubMed

20.

Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Samuel S, Klarenbach SW, Curhan GC, Tonelli M, Alberta Kidney Disease Network (2014) Kidney stones and cardiovascular events: a cohort study. Clin J Am Soc Nephrol 9:506–512. https://doi.org/10.2215/CJN.04960513 CrossRefPubMed

21.

Ferraro PM, Tylor EN, Eisner BH, Gambaro G, Rimm EB, Mukamal KJ, Curhan GC (2013) History of kidney stones and the risk of coronary heart disease. JAMA 310:408–415. https://doi.org/10.1001/jama.2013.8780 CrossRefPubMedCentralPubMed

22.

Rule AD, Roger VL, Melton LJ 3rd, Bergstralh EJ, Li X, Peyser PA, Krambeck AE, Lieske JC (2010) Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 10:1641–1644. https://doi.org/10.1681/ASN.2010030253 CrossRef

23.

Eisner BH, Cooperberg MR, Curhan GC et al (2007) Nephrolithiasis and the risk of cardiovascular disease. J Urol 177:449CrossRef

24.

Reiner AP, Khan A, Eisner BH, Pletcher MJ, Sadetsky N, Dale Williams O, Polak JF, Jacobs DR, Stoller ML (2011) Kidney stones and subclinical atherosclerosis in young adults: Coronary Artery Risk Development in Young Adults (CARDIA) study. J Urol. https://doi.org/10.1016/j.juro.2010.10.086 PubMedCentralCrossRefPubMed

25.

Khan SR (2013) Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J Urol 189:803–811. https://doi.org/10.1016/j.juro.2012.05.078 CrossRefPubMed

26.

Rafleian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H (2014) Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 5:927–946

27.

Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473:317–325. https://doi.org/10.1038/nature10146 CrossRefPubMed

28.

Wang T, Palucci D, Law K, Yanagawa B, Yam J, Butany J (2012) Atherosclerosis: pathogenesis and pathology. Diagn Histopathol 18:461–467. https://doi.org/10.1016/j.mpdhp.2012.09.004 CrossRef

29.

Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876–1890. https://doi.org/10.1161/hq1201.100220 CrossRefPubMed

30.

Huang Y, Song L, Wu S, Fan F, Lopes-Virella MF (2001) Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 156:119–125. https://doi.org/10.1016/S0021-9150(00)00638-9 CrossRefPubMed

31.

Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V (1995) Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92:1565–1569

32.

Duarte M, Moresco RN, Bem AF (2008) [Assays for measurement of oxidized low-density lipoprotein and its application as a marker of cardiovascular risk]. Rev Bras Anal Clin 40:101–106

33.

Tsimikas S, Bergmark C, Beyer RW, Patel R, Pattison J, Miller E, Juliano J, Witztum JL (2003) Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndrome. J Am Coll Cardiol 41:360–370. https://doi.org/10.1016/S0735-1097(02)02769-9 CrossRefPubMed

34.

Goyal T, Mitra S, Khaidakov M, Wang X, Singla S, Ding Z, Liu S, Mehta JL (2012) Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheros Rep 14:150–159. https://doi.org/10.1007/s11883-012-0228-1 CrossRef

35.

Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Isenovic ER (2015) Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci 52:70–85. https://doi.org/10.3109/10408363.2014.992063 CrossRefPubMed

36.

Linna M, Ahotupa M, Löppönen MK, Irjala K, Vasnkari T (2013) Circulating oxidized LDL lipids, when proportioned to HDL-c, emerged as a risk factor of all-cause mortality in a population-based survival study. Age Ageing 42:110–113. https://doi.org/10.1093/ageing/afs074 CrossRefPubMed

37.

Santos AO, Fonseca FA, Fisher SM, Monteiro CM, Brandão SA, Póvoa RM, Bombig MT, Carvalho AC, Monteiro AM, Ramos E, Gidlund M, Figueiredo Neto AM, Izar MC (2009) High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin Chim Acta 406:113–118. https://doi.org/10.1016/j.cca.2009.06.005 CrossRefPubMed

38.

Medeiros AM, Von Mühlen CA, Gidlund MA, Bodanese R, Gottlieb MG, Bodanese LC (2010) Antibodies against oxLDL and acute coronary syndrome. Arq Bras Cardiol 95:47–54. https://doi.org/10.1590/S0066-782X2010005000063 CrossRefPubMed

39.

Nowak B, Szmyrka-Kaczmarek M, Durazińska A, Plaksej R, Borysewicz K, Korman L, Wiland P (2012) Anti-ox-LDL antibodies and anti-ox-LDL-B2GPI antibodies in patients with systemic lupus erythematosus. Adv Clin Exp Med 21:331–335PubMed

40.

Hasna A, Meiyappan K, Periyasam SG, Kalyaperumal M, Bobby Z, Subramaniam AV (2015) Is urolithiasis associated with increased levels of high sensitivity C-reactive protein and interleukin-6 in diabetic patients? J Clin Diagn Res 9:BC01–BC03. https://doi.org/10.7860/JCDR/2015/12489.5681 PubMedCentralCrossRefPubMed

41.

Yencilek E, Sari H, Yencilek F, Yeşil E, Aydın H (2017) Systemic endothelial function measured by flow-mediated dilation is impaired in patients with urolithiasis. Urolithiasis 45:545–552. https://doi.org/10.1007/s00240-016-0941-2 CrossRefPubMed

42.

Girona J, Manzanares JM, Marimón F, Cabré A, Heras M, Guardiola M, Ribalta J, Masana L (2008) Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. Nutr Metab Cardiovasc Dis 18:380–387. https://doi.org/10.1016/j.numecd.2007.04.002 CrossRefPubMed

43.

Kim S, Chang Y, Sung E, Kang JG, Yun KE, Jung HS, Hyun YY, Lee KB, Joo KJ, Shin H, Ryu S (2018) Association between sonographically diagnosed nephrolithiasis and subclinical coronary artery calcification in adults. Am J Kidney Dis 71:35–41. https://doi.org/10.1053/j.ajkd.2017.06.026 CrossRefPubMed

44.

Smith-Bindman R, Aubin C, Bailitz J et al (2014) Ultrasonography versus computed tomography for suspected nephrolithiasis. N Engl J Med 371:1100–1110. https://doi.org/10.1056/NEJMoa1404446 CrossRefPubMed

Title: Is oxidized low-density lipoprotein the connection between atherosclerosis, cardiovascular risk and nephrolithiasis?
Authors: Augustus Cesar Pinto de Freitas
Leuridan Cavalcante Torres
Maria do Carmo Menezes Bezerra Duarte
Marina Cadena da Matta
Dulce Elena Casarini
Nestor Schor
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Published in: Urolithiasis / Issue 4/2019
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-018-1082-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Is oxidized low-density lipoprotein the connection between atherosclerosis, cardiovascular risk and nephrolithiasis?

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Long-term effects of anatrophic nephrolithotomy on selective renal function

Predictors of spontaneous ureteral stone passage in the presence of an indwelling ureteral stent

Development of a two-stage in vitro model system to investigate the mineralization mechanisms involved in idiopathic stone formation: stage 1—biomimetic Randall’s plaque using decellularized porcine kidneys

Does leaving residual fragments after percutaneous nephrolithotomy in patients with positive stone culture and/or renal pelvic urine culture increase the risk of infectious complications?

Development of a two-stage model system to investigate the mineralization mechanisms involved in idiopathic stone formation: stage 2 in vivo studies of stone growth on biomimetic Randall’s plaque

Hypertension and renal impairment in patients with cystinuria: findings from a specialist cystinuria centre